Biotech Values

[oc631]

I don't want you further upsetting NVAX investors

There's a VRBPAC meeting May 16TH to choose the COVID vaccine strain selection for this season. Most developers are in agreement the selected variant will be JN.1. I suspect some developers, more specifically protein-based vaccine developers, are frontrunning this decision and are already manufacturing JN.1 COVID vaccine to give the appearance they are competitive in development time and scalability yet if there was another pandemic it would become clear they are not due to time constraints. This non-pandemic tender gives the semblance that PB COVID vaccines are competitive. As for the percent of the population brainwashed by fake news and unfounded adverse safety concerns with mRNA COVID vaccines, people that are demanding PB vaccines, that argument goes against scientific evaluation will fade away just like Donald Trump.